[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL3752501T3 - Inhibitory pd-1/pd-l1 - Google Patents

Inhibitory pd-1/pd-l1

Info

Publication number
PL3752501T3
PL3752501T3 PL19707975.9T PL19707975T PL3752501T3 PL 3752501 T3 PL3752501 T3 PL 3752501T3 PL 19707975 T PL19707975 T PL 19707975T PL 3752501 T3 PL3752501 T3 PL 3752501T3
Authority
PL
Poland
Prior art keywords
inhibitors
Prior art date
Application number
PL19707975.9T
Other languages
English (en)
Inventor
Evangelos Aktoudianakis
Aesop Cho
Zhimin Du
Michael Graupe
Lateshkumar Thakorlal LAD
Paulo A. MACHICAO TELLO
Jonathan William MEDLEY
Samuel E. Metobo
Prasenjit Kumar MUKHERJEE
Devan Naduthambi
Eric Q. PARKHILL
Scott Preston Simonovich
Neil H. Squires
Peiyuan Wang
William J. Watkins
Jie Xu
Kin Shing YANG
Christopher Allen Ziebenhaus
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of PL3752501T3 publication Critical patent/PL3752501T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL19707975.9T 2018-02-13 2019-02-12 Inhibitory pd-1/pd-l1 PL3752501T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862630187P 2018-02-13 2018-02-13
US201862640534P 2018-03-08 2018-03-08
US201862763116P 2018-04-19 2018-04-19
US201862747029P 2018-10-17 2018-10-17
PCT/US2019/017721 WO2019160882A1 (en) 2018-02-13 2019-02-12 Pd-1/pd-l1 inhibitors

Publications (1)

Publication Number Publication Date
PL3752501T3 true PL3752501T3 (pl) 2023-08-21

Family

ID=65576712

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19707975.9T PL3752501T3 (pl) 2018-02-13 2019-02-12 Inhibitory pd-1/pd-l1

Country Status (25)

Country Link
US (3) US10710986B2 (pl)
EP (2) EP4227302A1 (pl)
JP (2) JP7062792B2 (pl)
KR (3) KR102445054B1 (pl)
CN (2) CN118084940A (pl)
AU (3) AU2019222644B2 (pl)
BR (2) BR112020016466A2 (pl)
CA (1) CA3091015C (pl)
CL (1) CL2020002082A1 (pl)
CO (1) CO2020009861A2 (pl)
CR (1) CR20200347A (pl)
DO (1) DOP2020000154A (pl)
ES (1) ES2949664T3 (pl)
IL (2) IL300572A (pl)
MX (2) MX2020008404A (pl)
MY (1) MY196582A (pl)
PE (1) PE20210640A1 (pl)
PH (1) PH12020551244A1 (pl)
PL (1) PL3752501T3 (pl)
PT (1) PT3752501T (pl)
SG (1) SG11202007646UA (pl)
SI (1) SI3752501T1 (pl)
TW (2) TWI707849B (pl)
UA (1) UA126458C2 (pl)
WO (1) WO2019160882A1 (pl)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017289038B2 (en) 2016-06-27 2021-07-22 Chemocentryx, Inc. Immunomodulator compounds
US11130740B2 (en) 2017-04-25 2021-09-28 Arbutus Biopharma Corporation Substituted 2,3-dihydro-1H-indene analogs and methods using same
CA3070794A1 (en) 2017-07-28 2019-01-31 Chemocentryx, Inc. Immunomodulator compounds
KR102670486B1 (ko) 2017-08-08 2024-05-28 케모센트릭스, 인크. 마크로사이클릭 면역조절제
MX2020002611A (es) 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Activador especifico de akt3 y usos del mismo.
PL3752501T3 (pl) 2018-02-13 2023-08-21 Gilead Sciences, Inc. Inhibitory pd-1/pd-l1
EP3752192A4 (en) * 2018-02-14 2021-11-10 Mayo Foundation for Medical Education and Research OVERCOMING RESISTANCE TO THERAPY WITH INHIBITORS OF PD-1 / PD-L1 INTERACTIONS IN CANCER PATIENTS
EP3755311A4 (en) 2018-02-22 2021-11-10 ChemoCentryx, Inc. USEFUL INDANE-AMINES AS AN AGONISTS OF PD-L1
WO2019191624A1 (en) 2018-03-29 2019-10-03 Arbutus Biopharma, Inc. Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
EP3781556A1 (en) 2018-04-19 2021-02-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR102625712B1 (ko) 2018-07-13 2024-01-19 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
KR102635333B1 (ko) * 2018-10-24 2024-02-15 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
WO2020088357A1 (zh) * 2018-11-02 2020-05-07 上海再极医药科技有限公司 联苯类化合物、其中间体、制备方法、药物组合物及应用
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
WO2020232256A1 (en) 2019-05-15 2020-11-19 Chemocentryx, Inc. Triaryl compounds for treatment of pd-l1 diseases
CN114072135A (zh) 2019-06-20 2022-02-18 凯莫森特里克斯股份有限公司 治疗pd-l1疾病的化合物
CA3145303A1 (en) 2019-07-10 2021-01-14 Chemocentryx, Inc. Indanes as pd-l1 inhibitors
WO2021063404A1 (zh) 2019-09-30 2021-04-08 南京明德新药研发有限公司 作为pd-1/pd-l1小分子抑制剂的化合物及其应用
IL290999B1 (en) 2019-09-30 2024-10-01 Gilead Sciences Inc HBV vaccines and HBV treatment methods
CR20220216A (es) * 2019-10-16 2023-01-09 Chemocentryx Inc Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
WO2021076691A1 (en) * 2019-10-16 2021-04-22 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
CA3208912A1 (en) 2019-10-18 2021-04-22 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
EP4052040A1 (en) 2019-10-31 2022-09-07 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
US20230029157A1 (en) * 2019-11-26 2023-01-26 The Regents Of The University Of California Combination therapy for head and neck cancer
CN117736207A (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
EP4100381A4 (en) * 2020-02-03 2024-04-03 Arbutus Biopharma Corporation SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS OF USE THEREOF
AU2021219668A1 (en) 2020-02-14 2022-08-25 Gilead Sciences, Inc. Antibodies and fusion proteins that bind to CCR8 and uses thereof
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
EP4146345A2 (en) 2020-05-05 2023-03-15 Teon Therapeutics, Inc. Cannabinoid receptor type 2 (cb2) modulators and uses thereof
KR20230040993A (ko) * 2020-06-23 2023-03-23 케모센트릭스, 인크. 헤테로아릴-바이페닐 아미드 유도체를 사용한 암 치료 방법
AU2021329259A1 (en) 2020-08-17 2023-03-02 Aligos Therapeutics, Inc. Methods and compositions for targeting PD-L1
WO2022087416A1 (en) * 2020-10-22 2022-04-28 Actinium Pharmaceuticals, Inc. Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
CN112213487B (zh) * 2020-10-23 2021-10-29 郑州大学第一附属医院 Aste1在检测食管鳞癌中的应用
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
CN114507227B (zh) * 2020-11-17 2024-06-21 中国医学科学院药物研究所 苯并异噻唑类化合物、及其制法和药物组合物与用途
WO2022147302A1 (en) * 2020-12-30 2022-07-07 Chulalongkorn University 4-phenyl-indole derivatives and related uses
US20240165094A1 (en) * 2021-03-17 2024-05-23 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating melanoma
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
CN113135895A (zh) * 2021-04-30 2021-07-20 中国药科大学 一种新型联苯类衍生物及其制备方法与医药用途
TW202348237A (zh) 2021-05-13 2023-12-16 美商基利科學股份有限公司 TLR8調節化合物及抗HBV siRNA療法之組合
EP4341300A1 (en) 2021-05-21 2024-03-27 Cellectis S.A. Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors
EP4351564A1 (en) 2021-06-11 2024-04-17 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
KR20240019330A (ko) * 2021-06-11 2024-02-14 길리애드 사이언시즈, 인코포레이티드 Mcl-1 저해제와 항체 약물 접합체의 조합
AU2022298639B2 (en) 2021-06-23 2024-11-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022297367A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN115677665B (zh) * 2021-07-26 2024-04-19 中国药科大学 含联苯类衍生物及其医药用途
WO2023034530A1 (en) 2021-09-02 2023-03-09 Teon Therapeutics, Inc. Methods of improving growth and function of immune cells
AU2022375782A1 (en) 2021-10-28 2024-05-02 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CR20240173A (es) 2021-10-29 2024-06-20 Gilead Sciences Inc Compuestos de cd73
WO2023081730A1 (en) 2021-11-03 2023-05-11 Teon Therapeutics, Inc. 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
CN114085184B (zh) * 2021-11-17 2023-08-29 中山大学 含环丙烷结构的联苯类衍生物及其制备方法和应用
WO2023091932A1 (en) * 2021-11-17 2023-05-25 Cardiff Oncology, Inc. Cancer treatment using lsd1 inhibitors and plk1 inhibitors
WO2023097211A1 (en) 2021-11-24 2023-06-01 The University Of Southern California Methods for enhancing immune checkpoint inhibitor therapy
US20230220106A1 (en) 2021-12-08 2023-07-13 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
US20230203202A1 (en) 2021-12-08 2023-06-29 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
KR20240121760A (ko) * 2021-12-16 2024-08-09 알리고스 테라퓨틱스 인코포레이티드 Pd-l1을 표적화하기 위한 방법 및 조성물
AU2022419982A1 (en) 2021-12-22 2024-06-06 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
KR20240125012A (ko) 2021-12-22 2024-08-19 길리애드 사이언시즈, 인코포레이티드 이카로스 아연 핑거 패밀리 분해제 및 이의 용도
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
JP2023132064A (ja) 2022-03-10 2023-09-22 株式会社ジャパンディスプレイ 表示装置及び表示装置の製造方法
AU2023233730A1 (en) 2022-03-17 2024-09-26 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
AU2023240346A1 (en) 2022-03-24 2024-09-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
AU2023256670A1 (en) 2022-04-21 2024-10-17 Gilead Sciences, Inc. Kras g12d modulating compounds
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
WO2024015372A1 (en) 2022-07-14 2024-01-18 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
WO2024038356A1 (en) * 2022-08-16 2024-02-22 Arbutus Biopharma Corporation Synthesis of substituted 1-aryl-1'-heteroaryl compounds and substituted 1,1'-biheteroaryl compounds, and analogues thereof
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024097741A1 (en) 2022-11-04 2024-05-10 Gilead Sciences, Inc. Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
WO2024137852A1 (en) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024148209A1 (en) * 2023-01-06 2024-07-11 Staidson Biopharma Inc. Combination of antibodies specifically recognizing tnfr2 and pd-l1 or pd-1
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (497)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5059714A (en) 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
JP2000505471A (ja) 1996-02-28 2000-05-09 メルク エンド カンパニー インコーポレーテッド フィブリノーゲン受容体拮抗物質
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
JP2001329185A (ja) 1999-06-22 2001-11-27 Ricoh Co Ltd 反応生成物、該反応生成物を用いた電子写真感光体、及び該電子写真感光体を用いた電子写真装置と電子写真装置用プロセスカートリッジ
JP2001002661A (ja) 1999-06-22 2001-01-09 Ricoh Co Ltd ニトリル化合物及びその製造方法
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
HUP0203954A2 (hu) 1999-09-17 2003-03-28 Millennium Pharmaceuticals, Inc. Xa faktor inhibitorok
WO2001056989A2 (en) 2000-02-01 2001-08-09 Cor Therapeutics, Inc. Inhibitors of factor xa
JP2001335476A (ja) 2000-05-29 2001-12-04 Shionogi & Co Ltd 三環化合物の新規用途
WO2003024441A1 (fr) 2001-09-14 2003-03-27 Shionogi & Co., Ltd. Nouvelle utilisation de composes tricycliques
JP2004501913A (ja) 2000-06-23 2004-01-22 ブリストル−マイヤーズ　スクイブ　ファーマ　カンパニー ヘテロアリール−フェニル置換Ｘａ因子阻害剤
AU2001288617A1 (en) 2000-09-05 2002-03-22 Neogenesis Pharmaceuticals Inc. Methods for forming combinatorial libraries combining amide bond formation with epoxide opening
WO2002051775A2 (en) 2000-12-22 2002-07-04 Neogenesis Pharmaceuticals, Inc. Methods for forming combinatorial libraries using reductive amination
DE10104279A1 (de) 2001-01-31 2002-08-01 Heinz Langhals Kompetitive Prionen-Reagenzien und ihre Anwendung in Diagnostik und Therapie
FR2828206B1 (fr) 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
JP2006509801A (ja) 2002-12-11 2006-03-23 イーライ・リリー・アンド・カンパニー 新規ｍｃｈ受容体アンタゴニスト
JP4695395B2 (ja) 2002-12-13 2011-06-08 ニューロジェン・コーポレーション 疼痛治療用の併用療法
JP2006521357A (ja) 2003-03-24 2006-09-21 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャンネル遮断薬としてのビアリール置換６員複素環化合物
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
AU2005220882A1 (en) 2004-03-08 2005-09-22 Georgia State University Research Foundation, Inc Novel dicationic imidazo(1,2-a)pyridines and 5,6,7,8-tetrahydro-imidazo(1,2a)pyridines as antiprotozoal agents
JP2007530694A (ja) 2004-03-29 2007-11-01 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャネル遮断薬としてのビアリール置換ピラジノン
US7517910B2 (en) 2004-03-30 2009-04-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
ES2605792T3 (es) 2004-05-13 2017-03-16 Icos Corporation Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
US20060019967A1 (en) 2004-07-21 2006-01-26 Su-Ying Wu SARS CoV main protease inhibitors
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
US20080021069A1 (en) 2004-10-08 2008-01-24 Takeda Pharmaceutical Company Limited Receptor Function Regulating Agent
WO2006040646A1 (en) 2004-10-14 2006-04-20 Pfizer, Inc. Benzimidazole or indole amides as inhibitors of pin1
CA2584224A1 (en) 2004-11-03 2006-05-18 Arena Pharmaceuticals, Inc. Gpr41 and modulators thereof for the treatment of insulin-related disorders
CN101106991A (zh) 2005-01-28 2008-01-16 默克公司 抗糖尿病的双环化合物
CA2593858A1 (en) 2005-01-31 2006-08-10 Min Ge Antidiabetic bicyclic compounds
US8658666B2 (en) 2005-02-11 2014-02-25 3M Innovative Properties Company Substituted imidazoquinolines and imidazonaphthyridines
US20090142345A1 (en) 2005-03-15 2009-06-04 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
CA3151350A1 (en) 2005-05-09 2006-11-16 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
JP5084503B2 (ja) 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
TW201402124A (zh) 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
US7582803B2 (en) 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
AU2006304400A1 (en) 2005-10-19 2007-04-26 Merck Sharp & Dohme Corp. CETP inhibitors
WO2007049050A2 (en) 2005-10-27 2007-05-03 Heptahelix Ab Modulators of gpr40 for the treatment of diabetes
EP1953238B1 (en) 2005-11-04 2011-12-21 Eisai R&D Management Co., Ltd. Method for screening of substances using GPR40 and secretory phospholipase A2
US20100249175A1 (en) 2005-12-02 2010-09-30 Wilson W David Dicationic compounds which selectively recognize G-quadruplex DNA
PT1976828T (pt) 2005-12-29 2017-03-10 Celtaxsys Inc Derivados de diamina como inibidores de leucotrieno a4 hidrolase
WO2007096142A2 (en) 2006-02-22 2007-08-30 Philogen Spa Vascular tumor markers
EP2001844A2 (en) 2006-03-14 2008-12-17 Amgen, Inc Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
DE102006012251A1 (de) 2006-03-15 2007-11-08 Grünenthal GmbH Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln
RU2008141912A (ru) 2006-03-23 2010-04-27 Новартис АГ (CH) Противоопухолевые лекарства на основе антител к клеточным антигенам
MX2008012406A (es) 2006-03-31 2008-10-07 Novartis Ag Compuestos nuevos.
TW200815377A (en) 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
CA2651629A1 (en) 2006-05-09 2007-11-22 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
DE102006021872B4 (de) 2006-05-11 2008-04-17 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102006021878A1 (de) 2006-05-11 2007-11-15 Sanofi-Aventis Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102006021874B4 (de) 2006-05-11 2008-03-27 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-amino substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2007131621A1 (de) 2006-05-11 2007-11-22 Sanofi-Aventis 4,5-diphenyl-pyrimidinyl substituierte carbonsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JP5271895B2 (ja) 2006-05-15 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション 抗糖尿病性の二環式化合物
ES2379661T3 (es) 2006-06-27 2012-04-30 Takeda Pharmaceutical Company Limited Compuestos cíclicos condensados
WO2008014236A1 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008030520A1 (en) 2006-09-07 2008-03-13 Amgen Inc. Heterocyclic gpr40 modulators
WO2008037266A1 (en) 2006-09-25 2008-04-03 Universite Libre De Bruxelles Inhibitors of conventional protein kinase c isozymes and use thereof for treating inflammatory diseases
WO2008063768A2 (en) 2006-10-12 2008-05-29 Case Western Reserve University Compositions and methods for treating metabolic diseases
WO2008054674A2 (en) 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
AU2007314405A1 (en) 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
US7750048B2 (en) 2006-11-15 2010-07-06 Janssen Pharmaceutica Nv GPR40 agonists
WO2008065409A2 (en) 2006-12-01 2008-06-05 Betagenon Ab Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor
TW200838526A (en) 2006-12-01 2008-10-01 Astellas Pharma Inc Carboxylic acid derivatives
CA2670103C (en) 2006-12-04 2012-10-16 Boehringer Ingelheim International Gmbh Inhibitors of hiv replication
CN101600437A (zh) 2006-12-11 2009-12-09 诺瓦提斯公司 预防或治疗心肌缺血的方法
CA2672438A1 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
ES2415863T3 (es) 2006-12-22 2013-07-29 Incyte Corporation Heterociclos sustituidos como inhibidores de Janus Quinasas
HUE027641T2 (en) 2006-12-28 2016-11-28 Abbvie Inc Poly (ADP-ribose) polymerase inhibitors
WO2008090327A1 (en) 2007-01-22 2008-07-31 Betagenon Ab New combination for use in the treatment of cancer
WO2008090356A1 (en) 2007-01-25 2008-07-31 Betagenon Ab Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity
WO2008106202A1 (en) 2007-02-27 2008-09-04 Housey Gerard M Theramutein modulators
JP2010520892A (ja) 2007-03-12 2010-06-17 サイトピア・リサーチ・ピーティーワイ・リミテッド フェニルアミノピリミジン化合物およびその使用
EP2139843B1 (en) 2007-04-16 2013-12-25 Amgen, Inc Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
US8318781B2 (en) 2007-04-26 2012-11-27 Japan Science And Technology Agency G-protein-conjugated receptor agonist
US20090214529A9 (en) 2007-05-22 2009-08-27 Taigen Biotechnology Co., Ltd. Kinesin inhibitors
WO2008144925A1 (en) 2007-05-30 2008-12-04 Aegera Therapeutics Inc. Iap bir domain binding compounds
WO2008156656A2 (en) 2007-06-13 2008-12-24 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Method for making biaryl compounds, compounds made by the method, and method for their use
EP2002838A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma AG Verwendung von Aryl/Hetarylamid-Derivaten als Modulatoren des EP2-Rezeptors
CA2691444C (en) 2007-06-29 2016-06-14 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
US7928140B2 (en) 2007-08-02 2011-04-19 Amgen Inc. Benzothiazole PI3 kinase modulators for cancer treatment
CA2693208A1 (en) 2007-08-02 2009-02-05 Victoria Smith Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
TWI649303B (zh) 2007-08-17 2019-02-01 杜邦股份有限公司 製備４-乙醯基-ｎ-〔２-側氧基-２-〔（２，２，２-三氟乙基）胺基〕乙基〕-１-萘甲醯胺之化合物及方法
WO2009038204A1 (ja) 2007-09-17 2009-03-26 Pharma Frontier Co., Ltd. 新規長鎖脂肪酸誘導体化合物及びそれら化合物を有効成分とするｇタンパク質共役型レセプター作動剤
AU2008303975B2 (en) 2007-09-21 2013-05-16 Sanofi (Cyclopropyl-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
NZ584049A (en) 2007-09-21 2011-05-27 Sanofi Aventis (carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
AU2008310519B2 (en) 2007-10-08 2013-05-02 Advinus Therapeutics Private Limited Acetamide derivatives as glucokinase activators, their process and medicinal applications
MX2010003876A (es) 2007-10-10 2010-12-02 Amgen Inc Moduladores de gpr40 bifenilo- sustituidos.
JP2011016722A (ja) 2007-10-23 2011-01-27 Astellas Pharma Inc チアゾリジンジオン化合物
ES2498065T3 (es) 2007-10-24 2014-09-24 Astellas Pharma Inc. Compuesto de azolcarboxamida o sal del mismo
RU2490250C2 (ru) 2007-10-26 2013-08-20 Джапан Тобакко Инк. Спиросоединения и их фармацевтическое применение
AU2008319418B2 (en) 2007-10-29 2013-08-15 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2011515341A (ja) 2008-03-06 2011-05-19 アムジエン・インコーポレーテツド 代謝障害の治療に有用な立体配座的に制限されたカルボン酸誘導体
WO2009112445A1 (en) 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
MY192633A (en) 2008-07-08 2022-08-29 Incyte Holdings Corp 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
SI2310509T1 (sl) 2008-07-21 2015-07-31 Apogenix Gmbh TNFSF enoverižne molekule
US8586607B2 (en) 2008-07-28 2013-11-19 Syddansk Universitet Compounds for the treatment of metabolic diseases
ES2438496T3 (es) 2008-08-01 2014-01-17 Ventirx Pharmaceuticals, Inc. Formulaciones de agonistas de receptores de tipo toll y su uso
WO2010019702A2 (en) 2008-08-12 2010-02-18 Oncomed Pharmaceuticals, Inc. Ddr1-binding agents and methods of use thereof
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
TW201018667A (en) 2008-10-01 2010-05-16 Synta Pharmaceuticals Corp Compounds for inflammation and immune-related uses
EP2358656B1 (en) 2008-10-15 2014-01-01 Amgen, Inc Spirocyclic gpr40 modulators
WO2010066682A1 (en) 2008-12-08 2010-06-17 Euroscreen S.A. Compounds, pharmaceutical composition and methods for use in treating metabolic disorders
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
CA2745295C (en) 2008-12-09 2017-01-10 Gilead Sciences, Inc. Modulators of toll-like receptors
CN102264737A (zh) 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
AU2010205239B2 (en) 2009-01-19 2012-06-28 Daiichi Sankyo Company, Limited Cyclic compound having hetero atom
US20110312967A1 (en) 2009-01-23 2011-12-22 Schering Corporation Bridged and fused antidiabetic compounds
US20110312995A1 (en) 2009-01-23 2011-12-22 Schering Corporation Bridged and fused heterocyclic antidiabetic compounds
JP2012515779A (ja) 2009-01-23 2012-07-12 シェーリング コーポレイション ペンタフルオロスルホラン含有抗糖尿病化合物
EP2393810A1 (en) 2009-02-05 2011-12-14 Schering Corporation Phthalazine-containing antidiabetic compounds
EP2393359A4 (en) 2009-02-09 2012-10-03 Enanta Pharm Inc COMPOUND DIBENZIMIDAZOLE DERIVATIVES
WO2010096462A1 (en) 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
SG10201400235PA (en) 2009-02-27 2014-07-30 Enanta Pharm Inc Hepatitis c virus inhibitors
US9150554B2 (en) 2009-03-27 2015-10-06 Presidio Pharmaceuticals, Inc. Fused ring inhibitors of hepatitis C
BRPI1013937A2 (pt) 2009-04-22 2016-08-09 Astellas Pharma Inc compostos de ácido carboxílico
JP2012136438A (ja) 2009-04-22 2012-07-19 Astellas Pharma Inc テトラゾール化合物
PL3309157T3 (pl) 2009-05-13 2020-03-31 Gilead Pharmasset Llc Związki przeciwwirusowe
WO2010143733A1 (en) 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
TWI402070B (zh) 2009-06-11 2013-07-21 Abbott Lab 抗病毒化合物
TWI491606B (zh) 2009-07-13 2015-07-11 Gilead Sciences Inc 調節細胞凋亡信號之激酶的抑制劑
AU2010284241B2 (en) 2009-08-18 2016-11-10 Array Biopharma, Inc. Substituted benzoazepines as Toll-like receptor modulators
PT2467377T (pt) 2009-08-18 2017-04-04 Array Biopharma Inc Benzoazepinas substituídas como moduladores de recetores de tipo toll
GB0914856D0 (en) 2009-08-25 2009-09-30 Ark Therapeutics Ltd Compounds
WO2011031934A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
ES2661850T3 (es) 2009-09-14 2018-04-04 Gilead Sciences, Inc. Moduladores de receptores del tipo toll
BR112012007979A2 (pt) 2009-10-06 2016-03-29 Bristol Myers Squibb Co moduladores de gpr40 de pirrolidina
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
AU2010310813B2 (en) 2009-10-22 2015-06-18 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
AU2010312365A1 (en) 2009-10-30 2012-06-07 Mochida Pharmaceutical Co.,Ltd. Novel 3-hydroxy-5-arylisoxazole derivative
WO2011057214A2 (en) 2009-11-09 2011-05-12 Neurogenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
WO2011066241A1 (en) 2009-11-25 2011-06-03 Schering Corporation Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
CA2784528C (en) 2009-12-18 2018-05-01 Euroscreen Sa Pyrrolidine carboxylic acid derivatives, pharmaceutical composition and methods for use in treating metabolic disorders as agonists of g-protein coupled receptor 43 (gpr43)
WO2011076732A1 (en) 2009-12-21 2011-06-30 Euroscreen S.A. Compounds, pharmaceutical composition and methods for use in treating gastrointestinal disorders
WO2011076734A1 (en) 2009-12-21 2011-06-30 Euroscreen S.A. Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
RU2567755C2 (ru) 2009-12-25 2015-11-10 Мотида Фармасьютикал Ко., Лтд. Новое производное 3-гидрокси-5-арилизотиазола
WO2011080755A1 (en) 2009-12-29 2011-07-07 Advinus Therapeutics Private Limited Fused nitrogen heterocyclic compounds, process of preparation and uses thereof
WO2011082400A2 (en) * 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
WO2011092284A1 (en) 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
MX2012009088A (es) 2010-02-04 2012-12-05 Gilead Biologics Inc Anticuerpos que se enlazan a lisil oxidasa-tipo2 (loxl2) y metodos de uso para los mismos.
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
WO2011119870A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
TW201139438A (en) 2010-03-24 2011-11-16 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
KR20130073884A (ko) 2010-03-30 2013-07-03 노파르티스 아게 Ｄｇａｔ1 억제제의 용도
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
KR20130079429A (ko) 2010-05-12 2013-07-10 벤더르빌트 유니버시티 헤테로시클릭 설폰 mglur4 알로스테릭 강화제, 조성물 및 신경 기능이상을 치료하는 방법
US9145451B2 (en) 2010-05-13 2015-09-29 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhbiting G protein coupled receptor activity
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
MX2012013622A (es) 2010-05-31 2013-02-01 Ono Pharmaceutical Co Derivado de purinona.
WO2011151436A2 (en) 2010-06-04 2011-12-08 Euroscreen S.A. Novel compounds, method for use them and pharmaceutical composition containing them
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
JP2012036168A (ja) 2010-07-15 2012-02-23 Daiichi Sankyo Co Ltd ヘテロ原子を有する環状化合物を含有する医薬組成物
JP5917511B2 (ja) 2010-07-20 2016-05-18 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチＣｏｕｎｃｉｌ Ｏｆ Ｓｃｉｅｎｔｉｆｉｃ ＆ Ｉｎｄｕｓｔｒｉａｌ Ｒｅｓｅａｒｃｈ 規則性メソポーラスチタノケイ酸塩およびその調製のための方法
EP2595613B1 (en) 2010-07-22 2019-01-09 The U.S.A. as represented by the Secretary, Department of Health and Human Services Compounds for use in a method of preventing or treating viral infection
SG10201506703VA (en) 2010-08-27 2015-10-29 Gilead Biologics Inc Antibodies To Matrix Metalloproteinase 9
WO2012036168A1 (ja) 2010-09-14 2012-03-22 北海道公立大学法人札幌医科大学 筋ジストロフィーを処置するための組成物
US8999967B2 (en) 2010-09-29 2015-04-07 Presidio Pharmaceuticals, Inc. Tricyclic fused ring inhibitors of hepatitis C
RU2587061C2 (ru) 2010-10-01 2016-06-10 Вентиркс Фармасьютикалз, Инк. Способы лечения аллергических заболеваний
KR101866893B1 (ko) 2010-10-01 2018-06-14 벤티알엑스 파마슈티칼스 인코포레이티드 Tlr 아고니스트의 치료적 용도 및 병용 요법
US9040525B2 (en) 2010-10-08 2015-05-26 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
US9474275B2 (en) 2010-11-15 2016-10-25 Bayer Intellectual Property Gmbh Cyanoenamines and their use as fungicides
CA3095528C (en) 2010-11-17 2023-07-18 Gilead Pharmasset Llc Antiviral compounds
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
EP2646425B1 (en) 2010-12-01 2015-06-10 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome
WO2012078802A1 (en) 2010-12-08 2012-06-14 Takeda Pharmaceutical Company Limited PREPARATION OF SUBSTITUTED-4,5-DIHYDROPYRROLO[4,3,2-de][2,6]NAPHTHYRIDIN-3(1H)-ONES
CN103492406B (zh) 2010-12-09 2022-07-26 宾夕法尼亚大学董事会 嵌合抗原受体-修饰的t细胞治疗癌症的用途
UY33775A (es) 2010-12-10 2012-07-31 Gilead Sciences Inc Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
EP2651920A4 (en) 2010-12-15 2014-12-17 Abbvie Inc ANTI-VIRAL COMPOUNDS
WO2012083059A1 (en) 2010-12-15 2012-06-21 Abbott Laboratories Anti-viral compounds
EP2651926A4 (en) 2010-12-15 2014-07-09 Abbvie Inc ANTI-VIRAL COMPOUNDS
WO2012083043A1 (en) 2010-12-15 2012-06-21 Abbott Laboratories Anti-viral compounds
US20150031884A1 (en) 2010-12-15 2015-01-29 Abbvie Inc. Anti-viral compounds
WO2012088438A1 (en) 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
PT2663555T (pt) 2011-01-12 2017-03-23 Array Biopharma Inc Benzoazepinas substituídas como moduladores de recetores tipo-toll
MX346387B (es) 2011-01-12 2017-03-02 Ventirx Pharmaceuticals Inc Benzoazepinas sustituidas como moduladores de receptores tipo toll.
RU2013138372A (ru) 2011-01-19 2015-02-27 Галапаго Нв Производные азетидина, применяемые для лечения метаболических и воспалительных заболеваний
CA2825306C (en) 2011-01-25 2019-02-26 The Regents Of The University Of Michigan Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
ES2732311T3 (es) 2011-02-07 2019-11-21 Univ Washington Compuestos de manósidos y procedimientos de uso de los mismos
MA34956B1 (fr) 2011-02-12 2014-03-01 Globeimmune Inc Therapeutique a base de levure pour infection chronique par l'hepatite b
CN103492348A (zh) 2011-02-17 2014-01-01 武田药品工业株式会社 旋光的二氢苯并呋喃衍生物的制备方法
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
ES2887303T3 (es) 2011-04-08 2021-12-22 Janssen Sciences Ireland Unlimited Co Derivados de pirimidina para el tratamiento de infecciones víricas
CN104470886A (zh) 2011-04-08 2015-03-25 赛丹思科大学 用于治疗代谢疾病的邻-氟取代的化合物
CN103517898B (zh) 2011-04-27 2015-09-30 持田制药株式会社 新的3-羟基异噻唑 1-氧化物衍生物
WO2012154608A1 (en) 2011-05-06 2012-11-15 Intellikine, Llc Reactive mtor and pi3 kinase inhibitors and uses thereof
JP5659189B2 (ja) 2011-05-13 2015-01-28 富士フイルム株式会社 非共鳴２光子吸収材料、非共鳴２光子吸収記録材料、記録媒体、記録再生方法及び非共鳴２光子吸収化合物
EP2709989B8 (en) 2011-05-18 2018-04-18 Janssen Sciences Ireland UC Quinazoline derivatives for the treatment of viral infections and further diseases
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
WO2013009259A1 (en) 2011-07-14 2013-01-17 Biochromix Pharma Ab Novel compounds and their use in therapy
TWI537262B (zh) 2011-08-17 2016-06-11 美國禮來大藥廠 供治療糖尿病使用之新穎１，２，３，４－四氫喹啉衍生物
US9550835B2 (en) 2011-08-23 2017-01-24 Chugai Seiyaku Kabushiki Kaisha Anti-DDR1 antibody having anti-tumor activity
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
CN104024257A (zh) 2011-10-04 2014-09-03 吉利德卡利斯托加有限责任公司 Pi3k的新的喹喔啉抑制剂
WO2013057743A1 (en) 2011-10-21 2013-04-25 Connexios Life Sciences Pvt. Ltd Process for the preparation of an aryl oxime and salts thereof
KR20180034705A (ko) 2011-11-29 2018-04-04 오노 야꾸힝 고교 가부시키가이샤 퓨리논 유도체 염산염
MX359634B (es) 2011-12-21 2018-10-03 Novira Therapeutics Inc Agentes antivirales contra la hepatitis b.
EP2800736A1 (en) 2012-01-04 2014-11-12 Sanofi 3-[4-(phenylaminooxalylamino)phenyl]hex-4-ynoic acids, process for preparation thereof and use thereof as a medicament
KR102036547B1 (ko) 2012-01-12 2019-10-25 지앙수 헨그루이 메디슨 컴퍼니 리미티드 다중고리 유도체들, 제조 방법 그리고 그것들의 약제 용도
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6215230B2 (ja) 2012-01-16 2017-10-18 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ イオンチャネルのモジュレーターとしてのピラン−スピロ環式ピペリジンアミド
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
WO2013116562A1 (en) 2012-02-03 2013-08-08 Gilead Calistoga Llc Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
NZ627036A (en) 2012-02-08 2016-03-31 Janssen Sciences Ireland Uc Piperidino-pyrimidine derivatives for the treatment of viral infections
EP2816032A4 (en) 2012-02-13 2015-09-30 Takeda Pharmaceutical AROMATIC CORE COMPOUND
WO2013122028A1 (ja) 2012-02-13 2013-08-22 武田薬品工業株式会社 芳香環化合物
EP2820005A1 (en) 2012-02-28 2015-01-07 Piramal Enterprises Limited Phenyl alkanoic acid derivatives as gpr agonists
US8642585B2 (en) 2012-03-26 2014-02-04 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
EP2831060B1 (en) 2012-03-31 2016-05-04 F.Hoffmann-La Roche Ag Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
WO2013154163A1 (ja) 2012-04-11 2013-10-17 持田製薬株式会社 新規５－アリール－１，２－チアジナン誘導体
US8809376B2 (en) 2012-04-30 2014-08-19 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
CN104583194A (zh) 2012-05-11 2015-04-29 艾伯维公司 作为nampt抑制剂的哒嗪和吡啶衍生物
JP2015516436A (ja) 2012-05-11 2015-06-11 アッヴィ・インコーポレイテッド Ｎａｍｐｔ阻害薬
US8633182B2 (en) 2012-05-30 2014-01-21 Boehringer Ingelheim International Gmbh Indanyloxyphenylcyclopropanecarboxylic acids
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
JP6209600B2 (ja) 2012-06-08 2017-10-04 ギリアード サイエンシーズ， インコーポレイテッド フラビウイルス科ウイルスの大環状阻害剤
EA026235B1 (ru) 2012-06-08 2017-03-31 Джилид Сайэнс, Инк. Макроциклические ингибиторы вирусов flaviviridae
WO2014014530A1 (en) 2012-07-17 2014-01-23 Mylari Banavara L Ursolic acid salts for treating diabetes and obesity
JP2015127299A (ja) 2012-07-19 2015-07-09 武田薬品工業株式会社 固形製剤
WO2014019186A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
MY183534A (en) 2012-08-10 2021-02-25 Janssen Sciences Ireland Uc Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
CA2882743C (en) 2012-08-27 2021-11-30 Allergan, Inc. Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
KR20210081451A (ko) 2012-08-28 2021-07-01 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도
DK2890683T3 (en) 2012-08-28 2017-01-30 Janssen Sciences Ireland Uc MERGED BICYCLIC SULFAMOYL DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
ES2617906T3 (es) 2012-09-10 2017-06-20 F. Hoffmann-La Roche Ag 6-Aminoácido heteroarildihidropirimidinas para el tratamiento y la profilaxis de la infección por virus de la hepatitis B
US20140073631A1 (en) 2012-09-12 2014-03-13 Vymed Corporation Antiviral and antimicrobial compounds
UY35044A (es) 2012-09-24 2014-04-30 Gilead Sciences Inc ANTICUERPOS ANTI-dDr1
EP2903968B1 (en) 2012-10-02 2016-12-07 Gilead Sciences, Inc. Inhibitors of histone demethylases
JP6293765B2 (ja) 2012-10-10 2018-03-14 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染症および他の疾患の処置のためのピロロ［３，２−ｄ］ピリミジン誘導体
WO2014066834A1 (en) * 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
US20140128333A1 (en) 2012-11-02 2014-05-08 Maqui New Life S.A. Compounds, Compositions, and Methods for Decreasing Intestinal Glucose Uptake and Inducing Incretin Release
TWI692469B (zh) 2012-11-09 2020-05-01 南韓商Ｌｇ化學股份有限公司 Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
KR101268466B1 (ko) 2012-11-12 2013-06-04 유병수 사축형 윈드 터빈
SG11201503559TA (en) 2012-11-16 2015-06-29 Bristol Myers Squibb Co Pyrrolidine gpr40 modulators
KR20150082617A (ko) 2012-11-16 2015-07-15 브리스톨-마이어스 스큅 컴퍼니 디히드로피라졸 gpr40 조절제
EP2920165B1 (en) 2012-11-16 2016-09-28 Bristol-Myers Squibb Company Dihydropyrazole gpr40 modulators
US9663474B2 (en) 2012-11-16 2017-05-30 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections
MX2015006156A (es) 2012-11-20 2015-08-05 Vertex Pharma Compuestos utiles como inhibidores de endolamina 2,3-dioxigenasa.
CN104822675A (zh) 2012-11-28 2015-08-05 勃林格殷格翰国际有限公司 新的茚满基氧基二氢苯并呋喃乙酸
CA2894399A1 (en) 2012-12-06 2014-06-12 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
WO2014086712A1 (en) 2012-12-07 2014-06-12 Boehringer Ingelheim International Gmbh New indanyloxydihydrobenzofuranylacetic acids
RS56821B1 (sr) 2012-12-19 2018-04-30 Celgene Quanticel Research Inc Inhibitori histon demetilaze
BR112015014592A2 (pt) 2012-12-21 2017-07-11 Gilead Calistoga Llc composto, composição farmacêutica, e, método para o tratamento de um humano
BR112015014585A2 (pt) 2012-12-21 2017-07-11 Gilead Calistoga Llc composto, composição farmacêutica, e, método de tratamento de um ser humano
AU2013363957B2 (en) 2012-12-21 2018-03-22 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
EP2953681B1 (en) 2013-02-06 2017-03-15 Boehringer Ingelheim International GmbH New indanyloxydihydrobenzofuranylacetic acids
AU2014220717B2 (en) 2013-02-21 2018-03-29 Janssen Sciences Ireland Uc 2-aminopyrimidine derivatives for the treatment of viral infections
BR112015019836A2 (pt) 2013-02-22 2017-07-18 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
WO2014134243A1 (en) 2013-02-27 2014-09-04 Regents Of The University Of Michigan Pharmaceutical compounds and use of same in cancer and tauopathies
CN105263906B (zh) 2013-02-27 2018-11-23 吉利德科学公司 组蛋白脱甲基酶的抑制剂
HUE034820T2 (en) 2013-02-28 2018-02-28 Janssen Sciences Ireland Uc Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B
JP6387023B2 (ja) 2013-02-28 2018-09-05 ティウムバイオ カンパニー、リミテッドＴｉｕｍＢｉｏ Ｃｏ．， Ｌｔｄ． 三環式化合物およびその使用
JP6320506B2 (ja) 2013-03-12 2018-05-09 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
CA2904760A1 (en) 2013-03-13 2014-09-18 Genentech, Inc. Pyrazolo compounds and uses thereof
AU2014236711A1 (en) 2013-03-14 2015-09-17 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
PL2970211T3 (pl) 2013-03-15 2018-01-31 Quanticel Pharmaceuticals Inc Inhibitory demetylazy histonowej
WO2014145817A2 (en) 2013-03-15 2014-09-18 Children's Medical Center Corporation Novel therapeutic target for the treatment of cancers and related therapies and methods
CN104059039B (zh) 2013-03-22 2017-03-15 正大天晴药业集团股份有限公司 具有gpr40受体功能调节作用的稠环化合物
BR112015025052A2 (pt) 2013-04-03 2021-07-06 Janssen Sciences Ireland Uc derivados de n-fenil-carboxamida e o seu uso como medicamentos para o tratamento da hepatite b
CN104109115B (zh) 2013-04-16 2016-11-23 中国科学院上海药物研究所 一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途
WO2014170842A2 (en) 2013-04-17 2014-10-23 Piramal Enterprises Limited Substituted alkyl carboxylic acid derivatives as gpr agonists
KR101569522B1 (ko) 2013-04-18 2015-11-17 현대약품 주식회사 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
AU2014267198A1 (en) 2013-05-17 2015-11-05 F. Hoffmann-La Roche Ag 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
EP2997019B1 (en) 2013-05-17 2018-08-08 Janssen Sciences Ireland UC Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
WO2014187343A1 (zh) 2013-05-22 2014-11-27 四川海思科制药有限公司 苯并呋喃衍生物、其制备方法及其在医药上的应用
ES2667173T3 (es) 2013-06-14 2018-05-09 Gilead Calistoga Llc Inhibidores de fosfatidilinositol 3-quinasa
CN104507921B (zh) 2013-07-02 2017-02-22 四川海思科制药有限公司 苯并环丁烯类衍生物、其制备方法及其在医药上的应用
US10478445B2 (en) 2013-07-03 2019-11-19 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
CA2917767C (en) 2013-07-12 2022-05-03 Helmholtz-Zentrum Fur Infektionsforschung Gmbh Cystobactamides
CN104341407A (zh) 2013-07-24 2015-02-11 黄传满 喹唑啉类化合物及其制备方法和用途
WO2015011281A1 (en) 2013-07-25 2015-01-29 Janssen R&D Ireland Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
CN105143181B (zh) 2013-07-26 2017-12-26 四川海思科制药有限公司 三元并环羧酸类衍生物、其制备方法及其在医药上的应用
EA029281B1 (ru) 2013-07-30 2018-03-30 Джилид Коннектикут, Инк. Полиморф ингибиторов syk
JP6397410B2 (ja) 2013-08-09 2018-09-26 武田薬品工業株式会社 芳香環化合物
CN104418801B (zh) 2013-08-19 2016-10-05 上海润诺生物科技有限公司 苯并哌啶环与苯并吗啉环类化合物、其制法及医药应用
US20160200734A1 (en) 2013-08-23 2016-07-14 Xinshan Kang Carboxylic acid compounds in treatment of diabetes mellitus
CN105612152A (zh) 2013-08-26 2016-05-25 普渡制药公司 氮杂螺[4.5]癸烷衍生物及其用途
WO2015028960A1 (en) 2013-08-28 2015-03-05 Piramal Enterprises Limited Substituted heterocyclic derivatives as gpr agonists and uses thereof
CN105246875A (zh) 2013-09-03 2016-01-13 四川海思科制药有限公司 茚满衍生物及其制备方法和在医药上的应用
US9872852B2 (en) * 2013-09-04 2018-01-23 Bristol-Myers Squibb Company Compounds useful as immunomodulators
HUE048874T2 (hu) 2013-09-06 2020-08-28 Aurigene Discovery Tech Ltd 1,2,4-oxadiazol-származékok, mint immunmodulátorok
EP3711762A1 (en) 2013-09-11 2020-09-23 INSERM (Institut National de la Santé et de la Recherche Médicale) A farnesoid x receptor agonsits foruse and pharmaceutical compositions for the treatment of chronic hepatitis b virus infection
EP3049396B1 (en) 2013-09-26 2017-11-15 Boehringer Ingelheim International GmbH Process and intermediates for preparing indanyloxydihydrobenzofuranyl acetic acid derivatives as gpr40 agonists
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9567299B2 (en) 2013-10-23 2017-02-14 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CN104592211B (zh) 2013-10-31 2018-10-16 广东东阳光药业有限公司 联苯类化合物及其用途
AP2016009176A0 (en) 2013-11-14 2016-04-30 Cadila Healthcare Ltd Novel heterocyclic compounds
JP6490686B2 (ja) 2013-11-14 2019-03-27 ノヴィラ・セラピューティクス・インコーポレイテッド アゼパン誘導体及びｂ型肝炎感染の治療方法
WO2015073342A1 (en) 2013-11-15 2015-05-21 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
MX2016006975A (es) 2013-11-27 2016-10-12 Euroscreen Sa Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
EP3074375B1 (en) 2013-11-28 2018-04-04 Boehringer Ingelheim International GmbH New indanyloxyphenylcyclopropanecarboxylic acids
WO2015084692A1 (en) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2015085238A1 (en) 2013-12-05 2015-06-11 The Regents Of The University Of California, A California Corporation Inhibitors of lpxc
TW201609722A (zh) 2013-12-13 2016-03-16 美國禮來大藥廠 新穎三唑并吡啶化合物
WO2015089809A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
UY35898A (es) 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.
KR20160095117A (ko) 2014-01-10 2016-08-10 일라이 릴리 앤드 캄파니 페닐-트리아졸로-피리딘 화합물
KR20160095114A (ko) 2014-01-10 2016-08-10 일라이 릴리 앤드 캄파니 이소프로필 트리아졸로 피리딘 화합물
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
EA201691261A1 (ru) 2014-01-30 2016-11-30 Ф. Хоффманн-Ля Рош Аг Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
WO2015119899A1 (en) 2014-02-06 2015-08-13 Merck Sharp & Dohme Corp. Antidiabetic compounds
DK3102572T3 (en) 2014-02-06 2019-02-04 Janssen Sciences Ireland Uc SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
CN106061978B (zh) 2014-03-07 2018-10-23 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的新的6-稠合的杂芳基二氢嘧啶
WO2015140717A1 (en) 2014-03-18 2015-09-24 Iteos Therapeutics Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
AU2015239886B2 (en) 2014-04-04 2018-02-01 Iomet Pharma Ltd Indole derivatives for use in medicine
LT3536685T (lt) 2014-04-04 2022-04-25 Pfizer Inc. Biciklinio sulieto heteroarilo arba arilo junginiai ir jų naudojimas kaip irak4 inhibitorių
JP2017515464A (ja) 2014-04-10 2017-06-15 シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート 細胞免疫療法のための方法および組成物
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
ES2671402T3 (es) 2014-05-07 2018-06-06 Bristol-Myers Squibb Company Moduladores de pirrolidina GPR40 para el tratamiento de enfermedades tales como diabetes
EP3140294A1 (en) 2014-05-07 2017-03-15 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators
PL3140296T3 (pl) 2014-05-07 2018-08-31 Bristol-Myers Squibb Company Pirolidynowe modulatory gpr40 do leczenia chorób takich jak cukrzyca
CN106459032B (zh) 2014-05-13 2019-04-05 豪夫迈·罗氏有限公司 治疗和预防乙型肝炎病毒感染的新的二氢喹嗪酮类
WO2015176267A1 (en) 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN106535884A (zh) 2014-06-06 2017-03-22 弗雷克萨斯生物科学公司 免疫调节剂
KR20170015504A (ko) 2014-06-13 2017-02-08 유니버시티 오브 로체스터 소분자 유출 펌프 억제제
GB201411236D0 (en) 2014-06-25 2014-08-06 Takeda Pharmaceutical Novel compounds
GB201411239D0 (en) 2014-06-25 2014-08-06 Takeda Pharmaceutical Novel compounds
TW201613878A (en) 2014-07-09 2016-04-16 Janssen Pharmaceutica Nv Pyrazine GPR40 agonists for the treatment of type II diabetes
WO2016012470A1 (en) 2014-07-25 2016-01-28 F. Hoffmann-La Roche Ag New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
WO2016018729A1 (en) 2014-07-29 2016-02-04 Merck Sharp & Dohme Corp. Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
WO2016022742A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016022448A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016022446A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
RU2664329C1 (ru) 2014-08-14 2018-08-16 Ф. Хоффманн-Ля Рош Аг Новые пиридазоны и триазиноны для лечения и профилактики заражения вирусом гепатита b
GB201414730D0 (en) 2014-08-19 2014-10-01 Tpp Global Dev Ltd Pharmaceutical compound
SG11201701182VA (en) 2014-08-27 2017-03-30 Gilead Sciences Inc Compounds and methods for inhibiting histone demethylases
WO2016032120A1 (ko) 2014-08-27 2016-03-03 씨제이헬스케어 주식회사 신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
US10538555B2 (en) 2014-09-11 2020-01-21 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
UY35733A (es) 2014-09-12 2016-04-01 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Inhibidores macrocíclicos de las interacciones proteína/proteína pd-1/pd-l1 y cd80(b7-1)/pd-l1 i.p.c.
CN107087409B (zh) 2014-09-19 2020-07-31 吕衍达 苯并杂环化合物及其应用
ES2881195T3 (es) 2014-09-26 2021-11-29 Gilead Sciences Inc Derivados de aminotriazina útiles como compuestos inhibidores de quinasas que se unen a TANK
JP6783230B2 (ja) 2014-10-10 2020-11-11 ジェネンテック， インコーポレイテッド ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物
EP3206691B1 (en) 2014-10-14 2018-09-19 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
MX2017004614A (es) 2014-10-17 2017-06-20 Hyundai Pharm Co Ltd Preparacion compuesta, que contiene derivado novedoso de acido 3-(4-(benciloxi)fenil)hex-4-inoico y otro ingrediente activo, para prevenir o tratar enfermedades metabolicas.
UY36371A (es) 2014-10-24 2016-04-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de indolcarboxamida inhibidores de quinasas tipo btk y tipo tec
KR101857146B1 (ko) 2014-10-28 2018-05-11 삼성에스디아이 주식회사 유기 광전자 소자 및 표시 장치
MX2017005719A (es) 2014-11-03 2017-12-07 Iomet Pharma Ltd Compuesto farmaceutico.
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
GB201419579D0 (en) 2014-11-03 2014-12-17 Iomet Pharma Ltd Pharmaceutical compound
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
AR102537A1 (es) 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
AU2015358400B2 (en) 2014-12-03 2020-09-10 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
CN107206088A (zh) 2014-12-05 2017-09-26 豪夫迈·罗氏有限公司 使用pd‑1轴拮抗剂和hpk1拮抗剂用于治疗癌症的方法和组合物
CA2966234A1 (en) 2014-12-15 2016-06-23 Bellicum Pharmaceuticals, Inc. Methods for controlled elimination of therapeutic cells
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
AR103222A1 (es) 2014-12-23 2017-04-26 Hoffmann La Roche Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina
EP3240537B1 (en) 2014-12-30 2020-09-09 F. Hoffmann-La Roche AG Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection
CN107109497A (zh) 2014-12-31 2017-08-29 豪夫迈·罗氏有限公司 通过实时PCR从细胞裂解物定量HBV cccDNA的高通量新方法
EP3242878B1 (en) 2015-01-08 2020-10-14 Impetis Biosciences Ltd. Bicyclic compounds, compositions and medicinal applications thereof
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
WO2016120186A1 (en) 2015-01-27 2016-08-04 F. Hoffmann-La Roche Ag Recombinant hbv cccdna, the method to generate thereof and the use thereof
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
CN108025006A (zh) 2015-02-06 2018-05-11 尤尼蒂生物技术公司 化合物及在治疗衰老相关病症中的用途
WO2016128335A1 (en) 2015-02-11 2016-08-18 F. Hoffmann-La Roche Ag Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
WO2016128908A1 (en) 2015-02-12 2016-08-18 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
KR20170125931A (ko) 2015-03-10 2017-11-15 오리진 디스커버리 테크놀로지스 리미티드 면역조절제로서의 3-치환된 1,3,4-옥사다이아졸 및 티아다이아졸 화합물
CN114213356A (zh) 2015-03-10 2022-03-22 奥瑞基尼探索技术有限公司 作为免疫调节剂的1,2,4-噁二唑和噻二唑化合物
BR112017019304A2 (pt) 2015-03-10 2018-05-08 Aurigene Discovery Technologies Limited compostos de 1,2,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores
CA2979142A1 (en) 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited Therapeutic cyclic compounds as immunomodulators
CA2979145A1 (en) 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
CN104876912B (zh) 2015-04-08 2017-07-21 苏州云轩医药科技有限公司 Wnt信号通路抑制剂及其应用
EP3294732B1 (en) 2015-05-15 2019-09-25 Gilead Sciences, Inc. Benzimidazole and imadazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase
MX2017015239A (es) 2015-05-29 2018-02-19 Juno Therapeutics Inc Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
WO2016197987A1 (zh) 2015-06-12 2016-12-15 杭州英创医药科技有限公司 作为Syk抑制剂和/或Syk-HDAC双重抑制剂的杂环化合物
EP3322420B1 (en) 2015-07-13 2021-12-29 Merck Sharp & Dohme Corp. Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein
JP6816107B2 (ja) 2015-08-07 2021-01-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング インダニルアミノピリジルシクロプロパンカルボン酸、医薬組成物及びこれらの使用
US9920040B2 (en) 2015-08-12 2018-03-20 Janssen Pharmaceutica Nv GPR40 agonists for the treatment of type II diabetes
US9856245B2 (en) 2015-08-12 2018-01-02 Janssen Pharmaceutica Nv GPR40 agonists for the treatment of type II diabetes
WO2017027310A1 (en) 2015-08-12 2017-02-16 Janssen Pharmaceutica Nv Gpr40 agonists for the treatment of type ii diabetes
WO2017031392A1 (en) 2015-08-20 2017-02-23 University Of Florida Research Foundation, Incorporated Lipid compounds for treatment of obesity, hypertension and metabolic syndrome
JP2018526405A (ja) 2015-09-09 2018-09-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ［｛［２，３−ジヒドロ−１Ｈ−インデン−１−イル］アミノ｝−２Ｈ，３Ｈ−フロ［３，２−ｂ］ピリジン−３−イル］酢酸、それらの医薬組成物および使用
WO2017049166A1 (en) 2015-09-17 2017-03-23 Novartis Ag Car t cell therapies with enhanced efficacy
US10745382B2 (en) 2015-10-15 2020-08-18 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2017070089A1 (en) 2015-10-19 2017-04-27 Incyte Corporation Heterocyclic compounds as immunomodulators
JP2018532756A (ja) 2015-11-04 2018-11-08 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ インドールアミン２，３−ジオキシゲナーゼを阻害するための医薬組成物と方法、及びその適応
PT3377488T (pt) 2015-11-19 2022-11-21 Incyte Corp Compostos heterocíclicos como imunomoduladores
KR20180093990A (ko) 2015-12-07 2018-08-22 고쿠리츠 다이가쿠 호진 교토 다이가쿠 Pd-1 시그널 저해제의 병용 요법
US20170174671A1 (en) 2015-12-17 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
MX2018007774A (es) 2015-12-22 2018-11-09 Incyte Corp Compuestos heterociclicos como inmunomoduladores.
US10800780B2 (en) 2015-12-24 2020-10-13 Genentech, Inc. TDO2 Inhibitors
EP3190103A1 (en) * 2016-01-08 2017-07-12 Rijksuniversiteit Groningen Inhibitors of the pd-1/pd-l1 protein/protein interaction
EP3416726A4 (en) 2016-02-17 2019-08-28 Children's Medical Center Corporation FFA1 (GPR40) as a therapeutic target for neural diseases or disorders related to angiogenesis
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US9798514B2 (en) 2016-03-09 2017-10-24 Spotify Ab System and method for color beat display in a media content environment
EP3432878A1 (de) 2016-03-23 2019-01-30 Symrise AG Homovanillinsäure-ester zum reduzieren oder inhibieren der fettsäureaufnahme im dünndarm
US10676458B2 (en) 2016-03-29 2020-06-09 Merch Sharp & Dohne Corp. Rahway Antidiabetic bicyclic compounds
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
WO2017180571A1 (en) 2016-04-11 2017-10-19 Janssen Pharmaceutica Nv Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes
US10195178B2 (en) 2016-04-11 2019-02-05 Janssen Pharmaceutica Nv GPR40 agonists in anti-diabetic drug combinations
US20190062272A1 (en) 2016-04-13 2019-02-28 Capten Therapeutics Inc. Small molecules for immunogenic treatment of cancer
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3459925B1 (en) 2016-05-23 2021-08-11 Tianjin Chase Sun Pharmaceutical Co., Ltd. Method for preparing 2-hydroxyl-4-(2, 3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative
WO2017201683A1 (en) 2016-05-25 2017-11-30 Merck Sharp & Dohme Corp. Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
US20190144545A1 (en) 2016-05-26 2019-05-16 Merck Patent Gmbh PD-1/PD-L1 Inhibitors for Cancer Treatment
PT3472167T (pt) 2016-06-20 2022-11-11 Incyte Corp Compostos heterocíclicos como imunomoduladores
AU2017289038B2 (en) 2016-06-27 2021-07-22 Chemocentryx, Inc. Immunomodulator compounds
US10590105B2 (en) 2016-07-08 2020-03-17 Bristol-Meyers Squibb Company 1,3-dihydroxy-phenyl derivatives useful as immunomodulators
CA3030773A1 (en) * 2016-08-03 2018-02-08 Arising International, Inc. Symmetric or semi-symmetric compounds useful as immunomodulators
EP3281937A1 (en) 2016-08-09 2018-02-14 Dompé farmaceutici S.p.A. Sulfonamides as gpr40- and gpr120-agonists
US10563620B2 (en) 2016-08-12 2020-02-18 Rolls-Royce North American Technologies Inc. Expandable exhaust cone
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
US10144706B2 (en) 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators
US10734026B2 (en) 2016-09-01 2020-08-04 Facebook, Inc. Systems and methods for dynamically providing video content based on declarative instructions
WO2018045142A1 (en) 2016-09-02 2018-03-08 Polaris Pharmaceuticals, Inc. Immune checkpoint inhibitors, compositions and methods thereof
WO2018051255A1 (en) 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Cyclic substituted-1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
WO2018051254A1 (en) 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators
WO2018053302A1 (en) 2016-09-19 2018-03-22 Ensemble Therapeutics Corporation Macrocyclic compounds for the inhibition of indoleamine-2,3-dioxygenase activity and use thereof
WO2018081047A1 (en) 2016-10-25 2018-05-03 Janssen Pharmaceutica Nv Cyclohexyl gpr40 agonists for the treatment of type ii diabetes
CN110088089B (zh) 2016-10-25 2023-08-29 勃林格殷格翰国际有限公司 苄基氨基吡啶基环丙烷甲酸、药物组合物及其用途
US10125101B2 (en) 2016-11-28 2018-11-13 Boehringer Ingelheim International Gmbh Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
KR102007633B1 (ko) 2016-12-15 2019-08-06 일동제약(주) 신규 페닐 프로피온 산 유도체 및 이의 용도
CN110072860B (zh) 2016-12-20 2022-09-02 百时美施贵宝公司 可用作免疫调节剂的化合物
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
AU2017378782A1 (en) 2016-12-20 2019-07-04 Merck Sharp & Dohme Corp. Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
GEP20227428B (en) 2016-12-22 2022-10-25 Incyte Corp Heterocyclic compounds as immunomodulators
JP7303108B2 (ja) 2016-12-22 2023-07-04 インサイト・コーポレイション 免疫調節剤としての二環式複素芳香環化合物
US20180177784A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
ES2899402T3 (es) 2016-12-22 2022-03-11 Incyte Corp Derivados de piridina como inmunomoduladores
PE20200005A1 (es) 2016-12-22 2020-01-06 Incyte Corp Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de internalizacion pd-l1
EP3564237A4 (en) 2016-12-29 2020-06-10 Shenzhen Chipscreen Biosciences Co., Ltd. UREA COMPOUND AND PRODUCTION METHOD AND USE THEREOF
CN110248929B (zh) 2017-01-26 2023-05-12 勃林格殷格翰国际有限公司 苄基氨基吡嗪基环丙烷甲酸、其药物组合物和用途
CN110198928B (zh) 2017-01-26 2023-08-29 勃林格殷格翰国际有限公司 苄氧基吡啶基环丙烷甲酸、其药物组合物和用途
US10253004B2 (en) 2017-01-26 2019-04-09 Boehringer Ingelheim International Gmbh Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
CN110177773B (zh) 2017-01-26 2023-08-25 勃林格殷格翰国际有限公司 苄基氨基吡啶基环丙烷羧酸、其药物组合物及其用途
EP3573969A1 (en) 2017-01-26 2019-12-04 Boehringer Ingelheim International GmbH Benzyloxypyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
CN110300755B (zh) 2017-02-08 2022-10-04 勃林格殷格翰国际有限公司 茚满基氨基氮杂二氢苯并呋喃乙酸、用于治疗糖尿病的药物组合物
CN110402248B (zh) 2017-03-15 2023-01-06 豪夫迈·罗氏有限公司 作为hpk1抑制剂的氮杂吲哚类
GB201704714D0 (en) 2017-03-24 2017-05-10 Caldan Therapeutics Ltd Pharmaceutical compounds
KR20190133714A (ko) 2017-03-27 2019-12-03 브리스톨-마이어스 스큅 컴퍼니 면역조정제로서 유용한 치환된 이소퀴놀린 유도체
TW201843139A (zh) 2017-03-30 2018-12-16 瑞士商赫孚孟拉羅股份公司 作為ｈｐｋ１之抑制劑的異喹啉
US10407424B2 (en) 2017-03-30 2019-09-10 Genentech, Inc. Naphthyridines as inhibitors of HPK1
CN110719903A (zh) 2017-03-31 2020-01-21 武田药品工业株式会社 芳族环化合物
AR111199A1 (es) 2017-03-31 2019-06-12 Takeda Pharmaceuticals Co Compuesto aromático agonista de gpr40
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
CN108794422B (zh) 2017-04-26 2022-07-01 南京圣和药业股份有限公司 作为pd-l1抑制剂的杂环类化合物
WO2019008156A1 (en) 2017-07-07 2019-01-10 Rijksuniversiteit Groningen INHIBITORS OF PROTEIN / PROTEIN INTERACTION PD-1 / PD-L1
CA3070794A1 (en) 2017-07-28 2019-01-31 Chemocentryx, Inc. Immunomodulator compounds
KR102670486B1 (ko) 2017-08-08 2024-05-28 케모센트릭스, 인크. 마크로사이클릭 면역조절제
CN111386116B (zh) 2017-08-18 2022-06-14 上海轶诺药业有限公司 一种具有pd-l1抑制活性的化合物、其制备方法及用途
WO2019059411A1 (en) 2017-09-20 2019-03-28 Chugai Seiyaku Kabushiki Kaisha DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
CN111051332B (zh) 2017-10-03 2024-09-06 百时美施贵宝公司 免疫调节剂
WO2019074241A1 (ko) 2017-10-11 2019-04-18 정원혁 페닐아세틸렌 유도체를 포함하는 pd-1과 pd-l1의 상호작용 억제제
CN109678796B (zh) 2017-10-19 2023-01-10 上海长森药业有限公司 Pd-1/pd-l1小分子抑制剂及其制备方法和用途
WO2019128918A1 (zh) 2017-12-29 2019-07-04 广州再极医药科技有限公司 芳香乙烯或芳香乙基类衍生物、其制备方法、中间体、药物组合物及应用
PL3752501T3 (pl) 2018-02-13 2023-08-21 Gilead Sciences, Inc. Inhibitory pd-1/pd-l1
EP3755311A4 (en) 2018-02-22 2021-11-10 ChemoCentryx, Inc. USEFUL INDANE-AMINES AS AN AGONISTS OF PD-L1
CR20240101A (es) 2018-03-08 2024-05-24 Incyte Corp COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-y (DIVISIONAL 2020-464)
GB201803736D0 (en) 2018-03-08 2018-04-25 Syngenta Participations Ag Improvements in or relating to organic compounds
BR102019004480B1 (pt) 2018-03-08 2023-03-28 Dow Agrosciences Llc Picolinamidas como fungicidas
WO2019174533A1 (zh) 2018-03-13 2019-09-19 广东东阳光药业有限公司 Pd-1/pd-l1类小分子抑制剂及其在药物中的应用
CN112105610B (zh) 2018-03-13 2024-01-26 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物
WO2019191624A1 (en) 2018-03-29 2019-10-03 Arbutus Biopharma, Inc. Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
CA3095758A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3774750A4 (en) 2018-04-03 2021-12-29 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
EP3781556A1 (en) 2018-04-19 2021-02-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
JP7328995B2 (ja) 2018-05-11 2023-08-17 インサイト・コーポレイション Ｐｄ－ｌ１免疫調節剤としてのテトラヒドロ－イミダゾ［４，５－ｃ］ピリジン誘導体
KR102625712B1 (ko) 2018-07-13 2024-01-19 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
CN112424185B (zh) 2018-07-13 2024-05-17 广州丹康医药生物有限公司 含苯环的化合物、其制备方法及应用
KR102635333B1 (ko) 2018-10-24 2024-02-15 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제

Also Published As

Publication number Publication date
US10710986B2 (en) 2020-07-14
IL276246B2 (en) 2023-07-01
EP3752501A1 (en) 2020-12-23
TW201942117A (zh) 2019-11-01
DOP2020000154A (es) 2020-09-15
PH12020551244A1 (en) 2021-05-17
US20230212155A1 (en) 2023-07-06
MY196582A (en) 2023-04-19
CN118084940A (zh) 2024-05-28
UA126458C2 (uk) 2022-10-05
CR20200347A (es) 2020-09-23
IL276246A (en) 2020-09-30
KR102445054B1 (ko) 2022-09-22
JP2022037169A (ja) 2022-03-08
JP2021513561A (ja) 2021-05-27
SG11202007646UA (en) 2020-09-29
MX2022014548A (es) 2023-01-11
JP7062792B2 (ja) 2022-05-06
AU2023202364A1 (en) 2023-05-25
TWI707849B (zh) 2020-10-21
TW202116759A (zh) 2021-05-01
MX2020008404A (es) 2020-09-25
CA3091015C (en) 2023-02-21
KR20200121323A (ko) 2020-10-23
AU2019222644A1 (en) 2020-09-03
WO2019160882A1 (en) 2019-08-22
CL2020002082A1 (es) 2020-12-11
KR102586510B1 (ko) 2023-10-12
TWI796596B (zh) 2023-03-21
CA3091015A1 (en) 2019-08-22
EP4227302A1 (en) 2023-08-16
US20190270727A1 (en) 2019-09-05
KR20220133305A (ko) 2022-10-04
US11555029B2 (en) 2023-01-17
PE20210640A1 (es) 2021-03-23
AU2021204222A1 (en) 2021-07-29
SI3752501T1 (sl) 2023-08-31
IL300572A (en) 2023-04-01
EP3752501B1 (en) 2023-04-19
PT3752501T (pt) 2023-07-12
BR112020016466A2 (pt) 2020-12-15
CO2020009861A2 (es) 2020-08-21
AU2021204222B2 (en) 2023-02-16
US20210053946A1 (en) 2021-02-25
BR102019002873A2 (pt) 2019-09-10
KR20230147740A (ko) 2023-10-23
IL276246B1 (en) 2023-03-01
ES2949664T3 (es) 2023-10-02
AU2019222644B2 (en) 2021-04-01
CN111712494A (zh) 2020-09-25
KR102708681B1 (ko) 2024-09-26

Similar Documents

Publication Publication Date Title
IL279991A (en) PD-1/PD-L1 inhibitors
IL276246A (en) PD-1/PD-L1 inhibitors
IL269466A (en) PD-1/PD-L1 inhibitors
IL283639A (en) kif18a inhibitors
IL263178A (en) Fidi-1 / Fidi-AL1 inhibitors for cancer treatment
IL254131A0 (en) Fidi-1 / Fidi-AL1 inhibitors for cancer treatment
EP3664829A4 (en) LIAISON OFFICERS AT PD-1 AND PD-L1
IL276813A (en) Arginase inhibitors
IL277778A (en) BCL6 inhibitors
IL289037A (en) Indanes as inhibitors of pd-l1
EP3817736A4 (en) PIKFYVE INHIBITORS
IL269347A (en) ip6k inhibitors
IL276013A (en) pi4kiiibeta inhibitors
EP3600301A4 (en) KDM4 INHIBITORS
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors
IL274550A (en) Dopamine-B-hydroxylase inhibitors
EP3768256A4 (en) PANTROPIC ENTRY INHIBITORS
IL288323A (en) Dopamine-b-hydroxylase inhibitors
GB201905476D0 (en) MAPA4K4 Inhibitors
GB201812462D0 (en) Inhibitors
GB201804439D0 (en) Dopamin-b-hydroxylase inhibitors
AU2014902472A0 (en) MRP4 inhibitors